| Drug Name |
Fingolimod |
| Drug ID |
BADD_D02464 |
| Description |
Multiple sclerosis or MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects.[A176474] Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010.[L12651]
Fingolimod is currently being studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus. Phase 2 clinical trials are currently underway and completion is expected in July 2020.[L12654] |
| Indications and Usage |
Fingolimod is a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability. |
| Marketing Status |
Not Available |
| ATC Code |
L04AA27 |
| DrugBank ID |
DB08868
|
| KEGG ID |
D10001
|
| MeSH ID |
D000068876
|
| PubChem ID |
107970
|
| TTD Drug ID |
D07UHS
|
| NDC Product Code |
54893-0026; 65035-201 |
| Synonyms |
Fingolimod Hydrochloride | 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride | FTY-720 | FTY 720 | FTY720 | Gilenya | Gilenia | Fingolimod |
